Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-12-09 5:37 pm Purchase | 2024-11-26 | 13G | Cidara Therapeutics, Inc. CDTX | Vivo Opportunity Fund Holdings L.P. | 600,157 5.500% | 600,157 (New Position) | Filing History |
2024-12-04 4:15 pm Purchase | 2024-11-26 | 13G | Cidara Therapeutics, Inc. CDTX | Venrock Healthcare Capital Partners III L.P. | 1,129,097 9.990% | 1,129,097 (New Position) | Filing History |
2024-12-03 4:34 pm Purchase | 2024-11-26 | 13G | Cidara Therapeutics, Inc. CDTX | TCG Crossover GP II, LLC | 1,005,901 9.200% | 1,005,901 (New Position) | Filing History |
2024-11-26 5:32 pm Purchase | 2024-11-26 | 13D | Cidara Therapeutics, Inc. CDTX | RA CAPITAL MANAGEMENT L.P. | 1,092,796 9.990% | 389,716 (+55.43%) | Filing History |
2024-11-14 4:22 pm Purchase | 2024-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 703,126 9.990% | 703,126 (New Position) | Filing History |
2024-07-29 4:45 pm Purchase | 2024-07-18 | 13G | Cidara Therapeutics, Inc. CDTX | BCLS Fund III Investments LP | 703,080 9.990% | 703,080 (New Position) | Filing History |
2024-07-29 4:31 pm Purchase | 2024-07-18 | 13G | Cidara Therapeutics, Inc. CDTX | Canaan XII L.P. | 1,400,000 9.990% | 1,400,000 (New Position) | Filing History |
2024-07-25 4:16 pm Purchase | 2024-07-18 | 13D | Cidara Therapeutics, Inc. CDTX | RA CAPITAL MANAGEMENT L.P. | 703,080 9.990% | 703,080 (New Position) | Filing History |
2024-02-14 4:51 pm Sale | 2023-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | Nantahala Capital Management LLC | 77,337 1.700% | -141,036 (-64.58%) | Filing History |
2024-02-14 10:18 am Purchase | 2023-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 463,776 9.990% | 120,720 (+35.19%) | Filing History |
2024-02-14 10:02 am Sale | 2023-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | Point72 Asset Management, L.P. | 62,511 1.400% | -130,889 (-67.68%) | Filing History |
2023-02-14 4:58 pm Sale | 2022-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | Nantahala Capital Management LLC | 218,373 6.100% | -45,150 (-17.13%) | Filing History |
2023-02-14 4:23 pm Sale | 2022-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | Point72 Asset Management, L.P. | 193,400 5.400% | -22,502 (-10.42%) | Filing History |
2022-02-15 1:09 pm Sale | 2021-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | Lytton, Laurence W. | 85,416 2.500% | -81,604 (-48.86%) | Filing History |
2022-02-14 4:48 pm Sale | 2021-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | Omega Fund V L.P. | 62,500 1.800% | -100,262 (-61.60%) | Filing History |
2022-02-14 4:41 pm Purchase | 2021-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | Point72 Asset Management, L.P. | 215,902 6.500% | 5,902 (+2.81%) | Filing History |
2022-02-14 08:30 am Purchase | 2021-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | Nantahala Capital Management LLC | 263,523 7.900% | 263,523 (New Position) | Filing History |
2022-02-11 4:48 pm Sale | 2021-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | BB Biotech AG | 0 0.000% | -141,125 (Position Closed) | Filing History |
2021-12-16 5:16 pm Purchase | 2021-12-14 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 343,056 10.300% | 119,982 (+53.79%) | Filing History |
2021-10-14 5:12 pm Purchase | 2021-10-13 | 13G | Cidara Therapeutics, Inc. CDTX | Point72 Asset Management, L.P. | 210,000 6.300% | 210,000 (New Position) | Filing History |